CEO transition with an insider promotion suggests continuity in strategy — no material change in operations or pipeline. The outgoing founder CEO staying on the board reduces disruption risk. Monitor the July effective date for any strategic shifts; the prior proxy fight context adds modest governance uncertainty. No immediate trading catalyst.
Price Chart
Executive Summary
Allogene Therapeutics announced a CEO transition: David Chang, M.D., Ph.D., will step down as President and CEO effective June 30, 2026, and will be succeeded by current EVP of R&D and CMO Zachary Roberts, M.D., Ph.D., effective July 1, 2026. Dr. Chang will remain on the board as a non-employee director. Dr. Roberts received a new compensation package including $680,000 base salary, options for 476,190 shares, and 134,530 RSUs.
Key Facts
- CEO David Chang departing June 30, 2026; Dr. Chang remains on board as non-employee director
- Zachary Roberts appointed President and CEO effective July 1, 2026; also appointed Class I director
- Dr. Roberts previously served as EVP R&D and CMO since Jan/Apr 2023
- New CEO base salary: $680,000; target cash incentive: 60% of salary
- Equity grants: option for 476,190 shares (4yr vest, 1yr cliff), RSU for 134,530 shares (4yr annual vest)
- Dr. Chang eligible for severance under Company's Change in Control and Severance Benefit Plan
- Cross-filing: DEFA14A filed 4/30/2026 — proxy fight materials contested election context
Financial Impact
Compensation package for new CEO includes $680K salary and equity grants covering ~611K shares total (option + RSU)
Risk Factors
- Founder CEO departure at a clinical-stage biotech may signal strategic or pipeline concerns
- Recent proxy contest context (DEFA14A 4/30) adds governance uncertainty
- Equity grants could cause modest future dilution (~0.4% on ~610K shares vs ~777M market cap)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-245484 |
| Document: 0001193125-26-245484-index-headers.html | 0001193125-26-245484 |
| Document: 0001193125-26-245484-index.html | 0001193125-26-245484 |
| Document: 0001193125-26-245484.txt | 0001193125-26-245484 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.23 (−2.00%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.23 (−38.13%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.23 (−39.66%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.23 (+41.39%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.23 (−37.82%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.23 (+40.82%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.23 (+40.82%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.23 (−43.55%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.23 (−43.55%) |
May 28, 2026 21w ago | Press Release | $2.17 $2.15 | ▼ −0.92% | ▼ −1.20% | $1.23 (−43.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers